Dragon Pharma
Dragon Pharma
You will save $48.00
Adipotide 10 mg
Product Information Compound Details
Active Substance Adipotide Prohibitin-targeting peptidomimetic (FTPP)
10 mg/vialStrength 10 mg/vial
Package 2 mL Vial Lyophilized powder
Form Lyophilized Powder
Drug Class Research Peptide
Manufacturer Dragon Pharma
Sequence CKGGRAKDC-GG-D(KLAKLAK)₂
$72.00
$120.00
Shipping :
International
U.S. Domestic
Out of stock
- Overview
- Profile
- Usage
- Safety
- Shipping
- Storage
- FAQ
- Reviews
Product Overview
Adipotide 10 mg by Dragon Pharma
Adipotide 10 mg is a lyophilized research peptide manufactured by Dragon Pharma, supplied as 10 mg per 2 mL vial for laboratory research purposes.
Adipotide Injectable
Adipotide 10 mg contains adipotide, a synthetic peptidomimetic also known as FTPP (prohibitin-targeting peptide) or CKGGRAKDC-GG-D(KLAKLAK)₂. Adipotide is a chimeric molecule composed of two functional domains: a homing sequence (CKGGRAKDC) that binds to prohibitin on the surface of blood vessels supplying white adipose tissue, and a proapoptotic sequence (D(KLAKLAK)₂) that triggers programmed cell death once internalized. The design intent is to selectively destroy the vasculature feeding white fat tissue, causing fat cells to be starved of nutrients and reabsorbed.
In preclinical research, adipotide has been studied extensively in animal models. In obese rhesus monkeys, daily subcutaneous injections over 28 days produced an average 11% reduction in body weight, a 27% decrease in abdominal fat, and marked improvements in insulin resistance. Obese mice lost up to 30% of body weight in earlier studies. Lean animals did not lose weight, suggesting the compound's effects may be selective for obese subjects with expanded white adipose tissue vasculature.
Adipotide has never been approved for human use. A Phase 1 clinical trial was initiated in 2012 in obese patients with castrate-resistant prostate cancer, but the trial was terminated due to dose-limiting nephrotoxicity. The primary safety signal in both primate and human studies was renal tubular toxicity, which was characterized as dose-dependent and reversible in animals but proved unacceptable in humans at therapeutic doses. Adipotide is not FDA-approved, has no legal compounding pathway, and is sold strictly for research purposes.
Key Benefits of Adipotide 10 mg
- Dual-domain peptidomimetic targeting prohibitin on adipose vasculature
- Preclinical research demonstrated significant fat mass reduction in obese primates
- Studied for improvements in insulin sensitivity and metabolic markers
- Lyophilized powder format for reconstitution and laboratory use
- 10 mg vial strength supports controlled research protocols
Formulation
Lyophilized Powder
Adipotide 10 mg is supplied as a lyophilized powder in a 2 mL vial. The powder requires reconstitution with an appropriate solvent before laboratory use. Once reconstituted, the solution should be handled according to standard research peptide protocols.
Product Profile
Adipotide Profile
Adipotide is a chimeric peptidomimetic that combines a prohibitin-binding homing sequence with a proapoptotic effector domain, designed to selectively ablate the vasculature supporting white adipose tissue.
Prohibitin-Targeting Peptidomimetic
Adipotide belongs to the class of ligand-directed peptidomimetics. Its structure consists of the sequence CKGGRAKDC-GG-D(KLAKLAK)₂. The CKGGRAKDC domain functions as a homing peptide that binds with high specificity to prohibitin (PHB), a protein expressed on the surface of vascular endothelial cells in white adipose tissue. The D(KLAKLAK)₂ domain is a cationic, amphipathic peptide that disrupts mitochondrial membranes, triggering apoptosis in cells that internalize the compound.
The mechanism of action is fundamentally distinct from other weight-management agents. Rather than modulating appetite or metabolism through receptor signaling, adipotide physically destroys the blood vessels that supply white fat tissue. When the vascular supply is ablated, fat cells are starved of nutrients and undergo reabsorption and metabolism. This approach has been described as a "new class of candidate drugs" for obesity treatment.
Preclinical research demonstrated that adipotide's effects were selective for white adipose tissue vasculature. In lean monkeys, no weight loss was observed, suggesting the drug's targeting was specific to the expanded vasculature associated with obesity. However, the selectivity was not absolute: prohibitin is also expressed in renal tissue, and the compound's clearance through the kidney led to dose-dependent renal tubular changes.
Research Status
Clinical Development Discontinued
Adipotide's Phase 1 clinical trial was terminated due to dose-limiting nephrotoxicity. The therapeutic window between effective fat-reducing doses and kidney-damaging doses proved too narrow for acceptable clinical use. Adipotide has never received marketing authorization in any jurisdiction.
Adipotide 10 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers a range of research peptides and compounds. Adipotide 10 mg is positioned as a research peptide with a unique mechanism targeting adipose vasculature, distinct from other metabolic research compounds.
For mitochondrial research compounds, Dragon Pharma offers MOTS-C and SS-31, which target different aspects of mitochondrial function. For fat loss research, AOD 9604 is a peptide fragment studied for lipolytic activity. Adipotide's vascular-targeting mechanism represents a fundamentally different research approach.
Dosage & Usage
Adipotide 10 mg Dosage & Usage
The information below is provided for educational reference only. Adipotide is a research compound that has never been approved for human use. No human safety or efficacy data exists, and the compound has been associated with significant renal toxicity in both animal studies and a terminated human clinical trial. Non-medical use is not supported by evidence and carries serious health risks.
Typical Dosage Ranges
No established human dosage exists for adipotide. In the terminated Phase 1 clinical trial, patients received daily subcutaneous injections for a single 28-day cycle, with dose escalation across up to five cohorts. The trial was terminated due to dose-limiting nephrotoxicity before a maximum tolerated dose was established. In preclinical primate studies, doses that produced meaningful fat loss also produced renal tubular changes. Common reference ranges for human use of this compound are not well characterized because no human use is supported by clinical evidence.
| Use Case | Research Reference | Frequency |
|---|---|---|
| Preclinical research (primate) | Doses titrated to effect | Daily for 28 days |
| Terminated Phase 1 trial | Escalating doses, up to 5 levels | Daily for 28 days |
| Human use | No established dosage | Not applicable |
Adipotide has no approved human dosing. The Phase 1 trial was terminated due to nephrotoxicity before a safe human dose could be established.
Stacking & Cycle Considerations
Adipotide is not an anabolic compound and is not stacked for muscle-building purposes. Its proposed mechanism of targeting adipose vasculature is unrelated to anabolic pathways. Because adipotide's safety profile is characterized by renal toxicity, combining it with other compounds that impose renal stress would be expected to compound risks. No clinical data exists on combining adipotide with any other compound.
For researchers interested in metabolic and mitochondrial compounds, Dragon Pharma offers MOTS-C and SS-31 as research peptides with different mechanisms of action and more favorable preclinical safety profiles.
Managing Side Effects
The primary safety signal for adipotide is renal toxicity. In primate studies, dose-dependent changes in renal proximal tubule function were observed, including decreased serum phosphorus and potassium, glucosuria, proteinuria, and increased transitional/renal epithelial cells in urine. These changes were generally characterized as mild and reversible in animals. In the human Phase 1 trial, nephrotoxicity proved to be dose-limiting and led to trial termination.
Given the mechanism of action, off-target effects from the proapoptotic domain are a theoretical concern if the compound fails to home specifically to adipose vasculature. The D(KLAKLAK)₂ domain disrupts mitochondrial membranes in any cell that internalizes it in sufficient quantity. Renal uptake and clearance of the compound likely contributed to the observed kidney toxicity.
Post-Cycle Therapy
Adipotide is not part of any post-cycle therapy protocol. It has no relationship to the hypothalamic-pituitary-gonadal axis. Its research focus has been on adipose tissue vasculature and metabolic endpoints, not hormonal recovery. PCT compounds such as Clomid and Nolvadex address different biological systems entirely.
Important
Research Use Only
Adipotide has never been approved for human use. Its clinical development was discontinued due to unacceptable kidney toxicity. The information above is for educational reference and does not constitute medical advice. Human use is not supported by evidence and is not recommended.
Safety & Information
Adipotide Safety Information
Adipotide is an experimental research compound that has never been approved for human use. Its clinical development was discontinued due to dose-limiting nephrotoxicity. No human safety data exists to support any human use.
Important Safety Information
Adipotide is not FDA-approved for any indication. It has no FDA drug application on file, no approved label, and no classification as a compoundable bulk drug substance under 503A or 503B. There is no legal pathway to obtain pharmaceutical-grade adipotide for human use in the United States. Products sold under this name through online vendors exist outside any regulatory framework and carry the additional risks of unverified identity, purity, and concentration.
Important
Not for Human Use
Adipotide is sold strictly for research purposes. It is not a dietary supplement, medication, or approved therapeutic agent. Human consumption is not recommended and may pose serious health risks. Product quality does not establish that human use is safe or appropriate.
Potential Adverse Effects
The primary adverse effect identified for adipotide is renal toxicity. In primate studies, dose-dependent changes in renal proximal tubule function were observed, including decreased serum phosphorus and potassium, urinary changes such as glucosuria and proteinuria, and increased transitional/renal epithelial cells. These changes were characterized as generally mild and reversible in animals, resolving during the recovery period.
In the Phase 1 human clinical trial, nephrotoxicity proved to be dose-limiting and led to trial termination. The therapeutic window between effective doses and kidney-damaging doses was too narrow for acceptable clinical use. The nephrotoxicity likely stems from the kidney's role in filtering and clearing the peptide, with the proapoptotic domain causing collateral damage to renal tubular epithelial cells during excretion.
Because the D(KLAKLAK)₂ domain disrupts mitochondrial membranes in any cell that internalizes it, off-target effects are a theoretical concern if the compound fails to home specifically to adipose vasculature. The compound's safety in primate models depended on the targeting selectivity of the CKGGRAKDC homing peptide.
Conditions Requiring Medical Evaluation
Adipotide has no approved indications and no established contraindications because no human use is supported. However, the documented renal toxicity profile raises particular concerns for individuals with pre-existing kidney disease or reduced renal function. Given that adipotide is not approved for any use, there are no populations for whom use is medically appropriate.
Monitoring During Therapy
No monitoring protocols exist for adipotide because it has no approved human use. In the terminated Phase 1 trial, safety monitoring included assessment of renal function, but specific monitoring guidelines have not been published in peer-reviewed form. For research settings, standard laboratory safety monitoring would apply.
Product Care
Storage & Handling
Store lyophilized powder according to standard research peptide protocols. Keep the vial securely stored and protected from conditions that could compromise the product. Inspect the product before use and do not use if it appears damaged or otherwise abnormal. Keep all research compounds out of the reach of children. Adipotide is classified as a non-approved substance under WADA category S0 and is prohibited in sport.
Further Research Information
Shipping & Authenticity
Shipping & Product Authenticity
Adipotide 10 mg is supplied through the official Dragon Pharma distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Adipotide 10 mg product, use the security code on the packaging and cross-check it on the Dragon Pharma official site. Official Dragon Pharma presentation and original packaging help reinforce product legitimacy and buyer confidence.
Storage
Adipotide 10 mg Storage
Proper storage conditions help preserve peptide integrity and stability throughout shelf life.
Recommended Conditions
Store lyophilized powder in a cool, dry place at controlled room temperature or refrigerated conditions (2–8°C) as appropriate for research peptides. Protect from excessive heat, moisture, and direct light. Keep the vial in its original packaging until use.
Once reconstituted, follow standard research peptide handling protocols for solution stability and storage. Do not use if the packaging appears damaged or if the powder shows signs of deterioration. Keep out of reach of children.
Quick Reference
Do & Don't
- Do store lyophilized powder refrigerated
- Do keep in original packaging
- Do inspect before use
- Don't expose to excessive heat
- Don't store in humid environments
- Don't use if packaging is compromised
Frequently Asked Questions
Adipotide 10 mg FAQ
Answers to common questions about Adipotide 10 mg, its research status, mechanism of action, and safety considerations.
What is Adipotide 10 mg used for?
Adipotide 10 mg is a research peptide studied for its ability to target and destroy the blood vessels supplying white adipose tissue. It has never been approved for human use, and its clinical development was discontinued due to kidney toxicity. It is sold strictly for laboratory research purposes.
How often should Adipotide 10 mg be used?
No established human dosage exists for adipotide. In the terminated Phase 1 clinical trial, patients received daily subcutaneous injections for a single 28-day cycle, but the trial was stopped due to dose-limiting nephrotoxicity. Human use is not supported by evidence.
Does Adipotide 10 mg require PCT?
What does adipotide do?
Adipotide is a chimeric peptidomimetic with two functional domains. The CKGGRAKDC domain binds to prohibitin on the surface of blood vessels supplying white adipose tissue. The D(KLAKLAK)₂ domain then triggers apoptosis, destroying those blood vessels and starving fat cells of nutrients. This causes fat tissue to be reabsorbed and metabolized.
How long does adipotide take to work?
In preclinical research, adipotide's effects were observed over a 28-day treatment period. Obese rhesus monkeys lost an average of 11% of body weight after 28 days of daily injections. Improvements in insulin resistance were noted during treatment. No human efficacy data exists.
Is adipotide the best peptide for fat loss?
Adipotide is not a viable fat loss agent for human use. Its clinical development was discontinued due to kidney toxicity. The research community generally regards its risk-benefit ratio as unacceptable, especially with safer alternatives available for weight management research.
What is the difference between adipotide and GLP-1 agonists?
Adipotide and GLP-1 agonists work through fundamentally different mechanisms. GLP-1 agonists modulate appetite and metabolism through receptor signaling and have completed Phase 3 trials and received FDA approval for specific indications. Adipotide physically destroys blood vessels supplying fat tissue, has never been approved for human use, and carries documented renal toxicity.
What is the difference between adipotide and AOD 9604?
Adipotide and AOD 9604 have different mechanisms. AOD 9604 is a peptide fragment studied for lipolytic activity through growth hormone-related pathways. Adipotide targets prohibitin on adipose vasculature and induces apoptosis of blood vessels. Adipotide's mechanism is more aggressive and carries documented renal toxicity.
Is 10 mg of adipotide a lot?
No human dosing standards exist for adipotide. The 10 mg vial strength is a research quantity, not a human dose. In the terminated Phase 1 trial, doses were escalated across up to five levels, but the trial was stopped before a safe dose was established. The 10 mg vial is intended for laboratory research use only.
What strength is Adipotide 10 mg?
Adipotide 10 mg is labeled at 10 mg of adipotide per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before laboratory use.
Does adipotide cause kidney damage?
Yes. Renal toxicity is the primary safety signal for adipotide. In primate studies, dose-dependent changes in renal proximal tubule function were observed, including glucosuria, proteinuria, and increased renal epithelial cells. In the human Phase 1 trial, nephrotoxicity was dose-limiting and led to trial termination. The kidney's role in filtering and clearing the peptide is believed to contribute to this toxicity.
Is adipotide approved for human use?
No. Adipotide has never been approved by the FDA or any regulatory authority for human use. It has no FDA drug application, no approved label, and no legal compounding pathway. Its clinical development was discontinued after the Phase 1 trial was terminated due to nephrotoxicity.
Related Offers
Lab Tested
Domestic & International
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Melanotan II Melanocortin Receptor Agonist
5 or 10 mg/vialVial Strength 5 mg or 10 mg
Package 1 × 2 mL Vial
Form Lyophilized Powder
Drug Class Research Peptide
Peptide Type Synthetic α-MSH Analog
Manufacturer Dragon Pharma
$27.00
$45.00
Domestic & International
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance GHK-CU Copper tripeptide (Gly-His-Lys-Cu)
10 or 50 mg/vialVial Strength 10 mg or 50 mg
Package 2 mL Vial Lyophilized powder
Form Lyophilized Powder
Drug Class Research Peptide
Manufacturer Dragon Pharma
Molecular Weight ~403.92 g/mol
$27.00
$45.00
Shipped International
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Formula Quadruple Peptide Blend
80 mg/vialGHK-Cu 50 mg
BPC-157 10 mg
TB-500 10 mg
KPV 10 mg
Total Strength 80 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Formula 4-Peptide Research Blend
Drug Class Research Peptide Blend
Manufacturer Dragon Pharma
$120.00
$200.00
Shipped USA Domestic
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance AICAR AMPK activator (Acadesine)
50 mg/vialStrength 50 mg/vial
Package 2 mL Vial Lyophilized powder
Form Lyophilized Powder
Drug Class Research Peptide / AMPK Activator
Manufacturer Dragon Pharma
Molecular Formula C9H14N4O5
$63.00
$105.00